Keyword: Lexicon Pharmaceuticals
Sanofi is set to pay Lexicon Pharmaceuticals $260 million to get out of a diabetes pact.
The study found the AAK1 inhibitor was well tolerated, teeing Lexicon up to advance the neuropathic pain prospect.
Sanofi and Lexicon aim to carve out a place for their experimental SGLT2/SGLT1 drug sotagliflozin in Type 1 diabetes.
In this week's EuroBiotech Report, Vicarius raises $22 million, GSK jilts Ionis, CellAct lands a $250 million deal and more.
Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.
Lexicon Pharmaceuticals has posted upbeat data from another phase 3 trial of its Sanofi-partnered dual SGLT1 and SGLT2 inhibitor sotagliflozin.
Lexicon Pharmaceuticals saw its shares bounce 8% premarket this morning on news out late last night that the FDA had approved its oral med Xermelo (telotristat ethyl) for patients with certain GI tumors suffering from the rare condition known as carcinoid syndrome diarrhea.
Lexicon Pharmaceuticals was up a bit in early trading on positive Phase II data for its sotagliflozin to treat diabetes. The company said the results confirmed its ongoing Phase III strategy.
The Texas-based company has now made arrangements to pay its final obligations to Symphony Icon upon an FDA approval of telotristat ethyl to treat carcinoid syndrome.
Lexicon Pharmaceuticals saw its shares jump by nearly 19% premarket this morning as it posted positive results for the late-stage study of its Sanofi-backed diabetes candidate sotagliflozin.